Well from the sound of it CF33 makes the old scale redundent.
I think it is far from clear that her-vaxx isnt worth the trouble. They are in negotiations. The market is slow and having $150m in cash they dont need to hurry. I heard in one of these threads that the most advanced trial on her-vaxx had only 19 patients. More data is need to get deals made.
Ann: Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration, page-159
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.6¢ |
Change
-0.004(6.67%) |
Mkt cap ! $411.5M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.5¢ | $1.481M | 26.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 400000 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 685507 | 4 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |